At month 24, a statistically significant difference of 12.9% in favour of Visudyne compared to placebo was observed (46.2% versus 33.3%, p=0.023).
24 kuu möödudes täheldati statistiliselt olulist 12, 9% - list erinevust Visudyne’ i kasuks võrreldes platseeboga (46, 2% versus 33, 3%, p=0, 023).